Daewoong Pharmaceutical said that Evolus, its U.S. and EU partner, has received sales approval for Nuceiva, its botulinum toxin (BTX) product, from the European Commission (EC).
|Daewoong headquarters in Samsung-dong, southern Seoul.|
Nuceiva is also known as Jeuveau in the U.S. and Nabota in Korea.
The EC approved the drug for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown when the severity of the facial lines has an important psychological impact in adults below 65 years of age.
With the approval, Evolus can now market the treatment in all 28 European Union member states plus Iceland, Norway, and Liechtenstein.
Evlous plans to start marketing the product from 2020.
"Product approval in Europe, following the U.S., is the result of the company proving Nabota's superior quality, safety and effectiveness at a global level," said Park Sung-soo, head of Daewoong's Nabota business division. "By entering the U.S. and Europe, the world's largest BTX markets, the company will actively promote Nabota's excellence on the global stage and further contribute to raising the status of local pharmaceutical companies."